Cardioselective beta-adrenoblockers in patients with stable angina pectoris. Comparison of efficacy and safety

Terapevticheskii Arkhiv

Volumn 78, Issue 9, 2006, Pages 43-48

  Duplyakov, D V ^a   Glukhova, V L ^a   Vozhdaeva, Z I ^a   Golovina, G A ^a  

^a NONE

Author keywords

Beta blockers; Ischemic heart disease

Indexed keywords

BENZOPYRAN DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; ETHANOLAMINE DERIVATIVE; METOPROLOL; NEBIVOLOL;

ANGINA PECTORIS; ARTICLE; BLOOD FLOW VELOCITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; ECHOGRAPHY; EXERCISE TOLERANCE; FEMALE; FOLLOW UP; HEART CONTRACTION; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANGINA PECTORIS; BENZOPYRANS; BETAXOLOL; BISOPROLOL; BLOOD FLOW VELOCITY; ECHOCARDIOGRAPHY; ETHANOLAMINES; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METOPROLOL; MIDDLE AGED; MYOCARDIAL CONTRACTION; TREATMENT OUTCOME;

EID: 33750440747     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Gibbons R. J., Abrams J., Chatterjee K. et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. 2002.
2. Management of stable angina pectoris. Recommendations of the Task Force of the European Society Cardiology. Eur. Heart. J. 1997; 18: 394-413.
3. de Vries R. J., van den Heuvel A. F., Lok D. J. et al. Nifedipine gastrointestinal therapeutic system versus atenolol in stable angina pectoris. The Netherlands Working Group on Cardiovascular Research (WCN). Int. J. Cardiol. 1996; 57: 143-150.
4. Fox K. M., Mulcahy D., Findlay I. et al. The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group. Eur. Heart J. 1996; 17: 96-103.
5. van de Ven L. L., Vermeulen A., Tans J. G. et al. Which drug to choose for stable angina pectoris: a comparative study between bisoprolol and nitrates. Int. J. Cardiol. 1995; 47: 217-223.
6. Gruppo Italiano per lo Studio della Sopravvivenza mell-Infarto miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-1122.
7. Waysbort J., Meshulam N., Brunner D. Isosorbide-5-mononitrate and atenolol in the treatment of stable exertional angina. Cardiology 1991; 79 (suppl. 2): 19-26.
8. Krepp H. P. Evaluation of the antianginal and anti-ischemic efficacy of slow-release isosorbide-5-mononitrate capsules, bupranolol and their combination, in patients with chronic stable angina pectoris. Cardiology 1991; 79 (suppl. 2): 14-18.
9. Kawanishi D. T., Reid C. L., Morrison E. C., Rahimtoola S. H. Response of angina and ischemia to long-term treatment in patients with chronic stable angina: a double-blind randomized individualized dosing trial of nifedipine, propranolol and their combination. J. Am. Coll. Cardiol. 1992; 19: 409-417.
10. Meyer T. E., Adnams C., Commerford P. Comparison of the efficacy of atenolol and its combination with slow-release nifedipine in chronic stable angina. Cardiovasc. Drugs Ther. 1993; 7: 909-913.
11. Steffensen R., Grande P., Pedersen F., Haunso S. Effects of atenolol and diltiazem on exercise tolerance and ambulatory ischaemia. Int. J. Cardiol. 1993; 40: 143-153.
12. Parameshwar J., Keegan J., Mulcahy D. et al. Atenolol or nicardipine alone is as efficacious in stable angina as their combination: a double blind randomised trial. Int. J. Cardiol. 1993; 40: 135-141.
13. Foale R. A. Atonolol versus the fixed combination of atenolol and nifedipine in stable angina pectoris. Eur. Heart J. 1993; 14: 1369-1374.
14. Czuriga I., Riecansky I., Bodnar J. et al. for the NEBIS Investigators; NEBIS Investigators Group. Comparison of the new cardioselective betablocker nebivolol with bisoprolol in hypertension: the Nebivolol. Bisoprolol Multicenter Study (NEBIS). Cardiovasc. Drugs. Ther. 2003; 17 (3): 257-263.
15. Burkart F., Pfisterer M., Steinmann E. Effects of bisoprolol in relation to metoprolol and bufuralol on left ventricular hemodynamics at rest and during exercise in chronic ischemic heart disease. J. Cardiovasc. Pharmacol. 1986; 8 (suppl. II): S78-S82.
16. Stoschitzky K., Stoschitzky G., Klein W. et al. Different effects of exercise on plasma concentration of nebivolol, bisoprolol and carvedilol. Cardiovasc. Drugs Ther. 2004; 18 (2): 135-138.
17. Poole-Wilson P. A., Swedberg K., Cleland J. C. F. et al. for the COMET investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362: 7-13.
18. Freemantle N., Cleland J., Young P. et al. Beta-blockade after myocardial infarction: systemic review and meta-regression analysis. Br. Med. J. 1999; 318: 1730-1737.
19. Lopes-Sendon J., Swedberg K., McMurray J. et al. Exepert consensus document on β-adrenergic receptor blockers. The Task Force on beta-blockers of the European Society of Cardiology. Euro Heart J. 2004; 25: 1341-1362.
20. Bruce R. A. Prognosis of coronary heart patients evaluated by data obtained by noninvasive methods. In: Roskamm H., ed. Prognosis of coronary heart disease progression of coronary arteriosclerosis. Berlin: Springer-Verlag; 1983. 16-23.
21. ACC/AHA Guidelines for the clinical application of echocardiography: executive summary. A report of the American College of Cardiology/American heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography. J. Am. Coll. Cardiol. 1997; 29: 862-879.
22. Celermater D. S., Sorensen K. E., Gooch V. M. et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340 (8828): 1111-1115.
23. Kakoki M., Hirata Y., Hayakawa H. et al. Effects of vasodilatory beta-adrenoceptor antagonists on endothelium-derived nitric oxide release in rat kidney. Hypertension 1999; 33 (pt 2): 467-471.